Babatunde O. Oyajobi, MBBS, PhD, MBAAssociate Professor
University of Lagos, Nigeria, MBBS (MD equivalent) 1983
University of Sheffield, England, PhD 1992
University of Texas at Austin, MBA 2007
Dr. Oyajobi joined the Department of Cellular & Structural Biology at the Health Science Center in September 2003. Prior to this, he did postdoctoral training on: (i) career development fellowship from the Arthritis & Rheumatism Council (now Arthritis UK) at the University of Sheffield in England; (ii) INSERM post-verte fellowship at INSERM Unité 349 (now Unité 606), Hôpital Lariboisiére in Paris, France; and (iii) fellowships from the International Myeloma Foundation and the Multiple Myeloma Research Foundation in the Departments of Medicine and Molecular Medicine respectively here at UT Health Science Center at San Antonio. He is a past recipient of a John Haddad Young Investigator Award from the American Society for Bone and Mineral Research (ASBMR) in 2001 and a Minority Scholar Award in Cancer Research from the American Association for Cancer Research (AACR) in 2005. He was also a recipient of an AACR Minority-Serving Institution Faculty Scholar Award each year from 2006 to 2009. He currently serves as a Chartered Member of the NIH/NCI-F (Institutional Training and Education) Subcommittee (till 2013) and has also served as an ad-hoc reviewer on several NIH/NCI Specialized Program of Research Excellence (SPORE) and Program Project (P01) Cluster grant review panels. He also served on the Education Committee of the ASBMR from 2007 through 2010, and is currently serving on the ASBMR Membership Development Committee through 2015. Dr Oyajobi, who is tenured, was faculty member-at-large on the Health Science Center's Executive Committee from September 2006 through August 2009. He is currently the Chair of the institution's Faculty Senate and member of the University of Texas (UT) System Faculty Advisory Council. He teaches on, and co-directs the Human Gross Anatomy Course for the Graduate School (CSBL5019) and the School of Health Professions (CSBL5013). He is also Chair, Committee on Graduate Studies in the department of Cellular & Structural Biology. Dr Oyajobi is an active member of the ASBMR, AACR and the American Society for Hematology (ASH).
Bone biology and cancer-induced bone diseases.
The Oyajobi laboratory is primarily interested in the interface between skeletal and cancer biology. Currently research in the lab is focused on multiple myeloma (MM), a malignancy of antibody-producing terminally differentiated B-cells (plasma cells) in which the primary site is the bone marrow cavity. Our studies aim to elucidate mechanisms mediating the osteolysis and bone deficit characteristic of MM. However, we are also interested in other tumors (e.g. breast cancer, lung cancer, neuroblastoma, renal cell carcinoma, etc) that are associated with skeletal metastastic lesions since the mechanistic basis for the associated bone diseases in these cases are likely to be similar to those underlying MM bone disease. Overall, our studies have a translational goal and involve identification of novel molecular targets for rational development of anti-tumor strategies and preclinical evaluation of novel anti-cancer agents effective against cancer-induced bone diseases in general. As part of this effort and in collaboration with other groups, we are currently refining existing mouse models of cancer-induced bone diseases (primarily MM and breast cancer) as well as developing and characterizing newer models that are better at predicting anti-tumor and anabolic bone efficacy of novel compounds.
Bone cell (osteoblast and osteoclast) culture
Cell proliferation and viability assays
Bone histology and histomorphometry
Promoter reporter assays
Whole body optical (fluorescence and bioluminescence) imaging in live mice
Non-invasive nuclear imaging of mouse skeleton
Dairaghi DJ*, Oyajobi BO*, Gupta A, McCluskey B, Miao S, Powers JP, Seitz LC, Wang Y, Zeng Y, Zhang P, Schall TJ, Jaen JC. (2012) CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood. 2012 Aug 16;120(7):1449-57. *Equal contribution
Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, Carew JS, Nawrocki ST. (2012) Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene. 2012 Jun 21;31(25):3023-38.
Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazón A, Azpilikueta A, Ochoa MC, Alfaro C, Solano S, Pérez-Gracia JL, Oyajobi BO*, Melero I*. (2008) Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008 Nov 1;14(21):6895-906. *Equal contribution
Oyajobi BO, Muñoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL, Story B, Grubbs B, Armstrong A, Dougall WC, Garrett IR, Mundy GR. (2007) Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther. 2007 Jun;6(6):1701-8.
Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Muñoz S, Zhao M, Mundy GR. (2007) Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol. 2007 Nov;139(3):434-8.
Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, Grubbs B, Zhao M, Chen D, Sherry B, Mundy GR. (2003) Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003 Jul 1;102(1):311-9.
Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. (2001) Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001 Mar 15;61(6):2572-8.